Getinge AB to Discuss Additional Quality and Supply Challenges Impacting Earnings in Q2 and FY 2023 Call Transcript
()- -
Hello, everyone, and thank you for joining this phone conference with short notice. My name is Mattias Perjos. I'm the CEO of Getinge. And with me, I have our CFO, Lars Sandstrom. So the reason for the call is the press release that we issued about half an hour ago regarding some additional quality and supply changes impacting our earnings in Q2 and the full year 2023.
So if we can please move to the next page, #2, we will start the conference. So we have experienced during the month of May and early June here, some additional quality and supply issues in our Acute Care therapies business area, and this is specifically related to the 2 product categories, cardiac assist and cardiopulmonary. And as a consequence of these quality and supply disturbances, we will have a negative impact of roughly SEK 400 million on EBITDA in the second quarter of 2023. And we also expect this impact, of course, to have -- to be visible in the full year results of 2023.
We can move to next page, #3,
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |